Bayer, J&J Sue Lupin to Block Copies of Blockbuster Xarelto Drug

March 2, 2021, 3:21 PM

Bayer and J&J’s Janssen said Lupin’s proposed generic version of the 2.5-milligram-tablet dosage of Xarelto infringes a patent for the blockbuster blood thinner because the copycat’s proposed labeling includes an indication for its use in reducing the risk of major cardiovascular events.

  • Bayer and J&J are seeking a court order blocking copies until the patent has expired, according to complaint filed Monday in federal court in Wilmington, Delaware
  • Patent, issued Nov. 10, covers use of the drug’s 2.5 mg dose, twice daily in tandem with 75-100 mg of aspirin, for reducing the risk of myocardial infarction, stroke or...

To read the full article log in. To learn more about a subscription click here.